Asia
A major factor behind the success of the smallpox eradication campaign was political commitment and leadership.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Ablaze has aligned itself with RayzeBio, giving Ablaze a solid start with an in-licensing agreement to bring Rayze’s products to the greater China market.
The whole world is watching the news about Omicron, but it’s obvious that it will be a week or two before enough is known about the new variant of concern.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The precision medicine company is developing mutant selective and isoform-specific drugs in non-conventional ways for well-known targets in the oncology and autoimmune spaces.
The FDA approved Takeda’s Livtencity (maribavir) for adults and children 12 years or older with post-transplant cytomegalovirus (CMV) infection.
Connect Biopharma shares plummeted 55% despite reported positive topline data from its Phase II trial of CBP-201 for adults with moderate-to-severe atopic dermatitis.
CStone forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.
PRESS RELEASES